Physician profile
Susannah E Johnson
NPI 1750606075
$2,962.42
in general payments reported to CMS, 2019-2025
17 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $320 · 2023: $917 · 2024: $1,440 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,444 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,443.88 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $753.60 | 2021-2025 | |
| Glaxosmithkline, LLC. | $499.48 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $433.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $387.14 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $198.80 | 2023-2024 | Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $194.24 | 2021-2024 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.24 | 2021-2023 | Xifaxan |
| Amgen INC. | $100.01 | 2021-2024 | Repatha, Otezla |
| Novo Nordisk INC | $79.62 | 2023-2025 | Ozempic, Rybelsus |
| Eisai INC. | $75.94 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $32.16 | 2021-2024 | |
| Medtronic, INC. | $18.88 | 2022 | |
| Edwards Lifesciences Corporation | $15.61 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Phathom Pharmaceuticals, INC. | $14.49 | 2024 | Voquezna |
| Alnylam Pharmaceuticals INC. | $13.08 | 2023 | Onpattro |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.34 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susannah Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.